Theralase Expands Clinical Study Sites for Bladder Cancer Treatment in the U.S.

Theralase Technologies Inc. has announced the addition of three new U.S.-based clinical study sites for its bladder cancer research: Associated Medical Professionals of NY, Urology of Indiana, and Central Ohio Urology Group. These sites will contribute to a phase II study focused on Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC).

Principal Investigators at these sites include Dr. Ilija Aleksic, Dr. Eugene Cone, and Dr. Benjamin Martin. Theralase's study employs Ruvidar, a lead drug activated by the TLC-3200 Medical Laser System. This study is designed in compliance with Health Canada and FDA guidance, aiming to offer patients an effective alternative to radical cystectomy.

To date, 75 patients have been treated, with a 61.9% complete response rate. The clinical study emphasizes safety, with no serious adverse events reported. Theralase plans to expand further, targeting regulatory approval by 2026.